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End-stage liver disease due to hepatitis C (HCV) and cirrhosis from alcohol (ALD) are the commonest indications for liver
transplantation in the western countries. Up to one third of HCV-infected transplant candidates have a history of signiﬁcant
alcohol intake prior to transplantation. However, there are few data available about the possible interaction between alcohol and
HCV in the post-transplant setting. Patients with both HCV and alcohol are more likely to die on the waiting list than those with
ALD and HCV alone. However, after transplantation, non-risk adjusted graft and patient survival of patients with HCV + ALD
are comparable to those of patients with HCV cirrhosis or ALD cirrhosis alone. In the short and medium term HCV recurrence
after transplant in patients with HCV + ALD cirrhosis does not seem more aggressive than that in patients with HCV cirrhosis
alone. A relapse in alcohol consumption in patients with HCV + ALD cirrhosis does not have a major impact on graft survival.
The evidence shows that, as is currently practiced, HCV + ALD as an appropriate indication for liver transplantation. However,
these data are based on retrospective analyses with relatively short follow-up so the conclusionsmust be treated with caution.
1.Background
In the Western world, the commonest indications for liver
transplantation are end-stage cirrhosis due to hepatitis C
virus (HCV) infection and, secondly, cirrhosis from alcohol
(ALD) [1]. The medium and longer term outcome of
patientsundergoingtransplantation forHCV-related cirrho-
sis isreduced because ofthe impact ofrecurrence ofhepatitis
C: this occurs almost invariably for those who have HCV
RNA prior to transplant.
Early reports suggested that HCV recurrence was a
relatively benign condition after liver transplantation [2–4]
but in 1999, Forman et al. [1], using the United Network
for Organ Sharing (UNOS) database of patients grafted
between 1992 and 1998, showed that HCV-infected patients
had worse patient and graft survival than those with chronic
cholestatic diseases, a similar outcome to those transplanted
for hepatitis B infection, autoimmune hepatitis, cryptogenic
cirrhosis, and ALD and better than that in patients under-
going transplantation for cancer. An analysis of the UNOS
database of patients grafted between 1990 and 1996 by
Roberts et al. [5] reached similar conclusion. In a relatively
large proportion of cases, HCV recurrence has an aggressive
course, with progression to cirrhosis within 5 years, resulting
in survival rates of less than 65% [6–8]. Treatment of the
HCV is, with current treatments, relatively ineﬀective and
a p p e a r st ob em o r et o x i ct h a ni nt h en a t i v el i v e r .
Alcoholic liver disease (ALD) is, for selected patients, an
excellent indication for liver transplantation, with outcomes
at least as good as for other indications and with a rate
of alcohol relapse acceptably low [9–11]. Nonetheless, it
remains a controversial indication for liver transplantation,
due to concerns that in some cases, the recipient will return
to a pattern of alcohol consumption, leading to graft failure,
noncompliance,orotherpotentiallyfatalcomplications[12].
Many patientswithalcoholicliverdisease haveassociated
hepatitis C viral (HCV) infection, and, conversely, many
people, infected with HCV drink above the recommended
limits for alcohol. There is mounting evidence that alcohol
abuse may accelerate the course of chronic hepatitis C
[13–18]. However, there are few data available about the
possible interaction between alcohol and HCV on the
posttransplant setting. Up to one third of HCV-infected
transplant candidates have a history of signiﬁcant alcohol
intake prior to transplantation [19], but the drinking habits
in HCV cirrhotic patients are often not always well explored.2 Journal of Transplantation
This probably has the eﬀect of signiﬁcantly underestimating
the impact of alcohol in causing end-stage liver disease
and overemphasizing the serious consequences of HCV
infection. Furthermore, after transplantation, patients with
HCVinfection (whether ornot associated with alcohol) tend
not to be monitored as closely for alcohol consumption
as those with HCV infection. The eﬀect of other agents,
such as use of illegal drugs (such as cannabis), is also not
well studied even though such agents are associated with
accelerated progression of HCV.
Inthispaper, we reviewthecurrentevidenceontheeﬀect
ofHCVandalcoholuseonthelisting andoutcomeafter liver
transplantation, compared to those with HCV or alcohol
alone, as a cause of the liver failure.
2.IstheOutcomeofLiverTransplantationin
PatientsWithHCV +ALDSimilarto Those
GraftedforHCVor ALDAlone?
Current evidence supports HCV + ALD as an appropriate
indication for liver transplantation, as highlighted by several
studies suggesting that patients with HCV + ALD have
similar graft and patient survival outcomes as patients who
undergo transplantation for HCV or ALD alone [20–25]
(Table 1).
In an early study, Dhar et al. in 1999 [20] showed little
diﬀerence in patients and graft survival between patients
undergoing transplantation for HCV alone or for HCV
infection plus alcohol. However the period of followup was
relatively short (mean 29 months). Subsequently, several
other early studies [21–23] have analyzed the consequences
of HCV infection in patients with ALD undergoing OLT,
and they found that pretransplant HCV infection in ALD
patients does not aﬀect the survival after OLT but these
series included only small numbers of patients and followup
was relatively short. Recently, Aguilera et al. [24]a n a l y z e d
retrospectively the clinical and histological outcome of 60
patients undergoing liver transplantation for cirrhosis of
mixedetiology(HCVandalcohol)andcompareditwiththat
of patients undergoing liver transplantation for HCV-related
cirrhosis (n = 170) or alcohol-related cirrhosis (n = 107).
They found that patients transplanted for HCV + ALD had
a better survival compared with patients with HCV alone,
and similar survival compared with patients with alcohol
a l o n e .P a t i e n ts u rvi v a la t1 ,5 ,a n d7y e a r sw a s8 6 % ,7 3 % ,a n d
63%, respectively, in the mixed group, 72%, 49%, and 43%,
respectively, in the HCV group, and 90%, 76%, and 67%,
respectively, in the alcohol group (HCV group versus mixed
group, P = .0001; mixed group versus alcohol group, P =
.74). Graft survival was signiﬁcantly lower in patients with
HCV-related cirrhosis compared to the other two groups.
T h er a t eo fr e t r a n s p l a n t a t i o nw a sh i g h e ri nt h em i x e dg r o u p ,
and the main cause of retransplantation in this group was
viral recurrence. The main causes of death in the mixed
group were recurrence of hepatitis C and complications
possibly related to excessive immunosuppression such as
sepsis. No diﬀerence were found in the incidence of severe
recurrent HCV disease or ﬁbrosis stage >1 at 1 year between
m i x e dg r o u pa n dH C Vg r o u p .T h ea u t h o r ss u g g e s tt h a tt h e
bettersurvival ofthe mixed groupmight be explained by two
factors: the greater use of antiviral treatment in the mixed
group versus the HCV group, because patients belonging to
the former group were younger and so more likely to receive
an antiviral treatment, and theyoungage is itself consistently
associated with better survival. In the mixed group, alcohol
was assumed to contribute mainly to the progression of liver
disease prior to transplantation. After transplantation, when
“alcohol factor” disappeared in the majority of patients, the
liver damage could be related only to recurrent hepatitis C,
similar to that occurring in patients without a history of
alcohol intake prior to transplantation; this would explain
the similar histologic HCV-progression in both groups in
this study.
The cumulative experience of multiple European trans-
plant centershaveconﬁrmed thatthesurvival rates following
liver transplantation in the European liver registries are
similar for patients with ALD and ALD plus viral etiology
(HCV and HBV), but patients with ALD plus HCV had
signiﬁcant lower survival compared to ALD plus HBV
infection [25].
Results show that concomitant infection with HCV
eliminates theprogressive improvementofsurvival overtime
in ALD patients. An adverse role of HCV coinfection in
patients transplanted for ALD liver cirrhosis is in keeping
with the ﬁnding of more aggressive liver damage was in ALD
plus HCV infected patients. In the same study, the authors
found that de novo tumors were a major cause of death in
the ALD group, but not in the HCV + ALD group and HCV
group (13.7%, 8%, and 5%, resp.). Patients transplanted
for ALD with and without associated HCV infection had a
signiﬁcantly higher incidence of death due to cardiovascular
events compared to patients with HCV alone (7.4%, 8%,
and 5.3%, resp.). Also, patient with ALD and ALD + HCV
had a greater incidence of deaths caused by social problems,
including suicide, compared to patients with HCV alone
(1.3%, 1.2%, and 0.6%, resp.) [25].
Interpretation of ﬁndings from registries will inevitably
have limitations: the data may be incomplete and deﬁ-
nitions and protocols for selection, transplantation, and
followup vary between participating centers. Furthermore,
case mix (as discussed below) may diﬀerbetween the groups.
Nonetheless, that the two large registries provide similar
outcomes implies that the conclusions are valid.
Thus,forthosetransplanted forHCV,itisimportant that
the recipient and the clinician are aware of the importance
of limiting alcohol consumption in order to prolong patient
and graft survival.
3.IsThere AnyDifferencein theBaseline
CharacteristicsofTransplanted Population
withBothHepatitisCand Alcoholism
ComparedwithPatientswithHCVor
AlcoholismAlone?
HCV + ALD patients undergoing liver transplantation are
usually younger than those transplanted for hepatitis C orJournal of Transplantation 3
Table 1: Patient survival after liver transplantation.
Diagnosis
1-year
survival
(%)
No. of
patients
3-year
survival
(%)
No. of
patients
5-year
survival
(%)
No. of
patients
10-year
survival
(%)
No. of
patients
Hepatitis C
Burra et al. [25] 81 4166 67 1906 54 475
Aguilera et al. [24] 7 26 8 4 98 3
Dhar et al. [20]8 0 2 5
Alcoholic Liver Disease
Burra et al. [25] 84 6301 73 2867 58 663
Aguilera et al. [24] 9 09 6 7 68 1
Burra et al. [21]6 4 3 3
Dhar et al. [20]9 0 2 2
Pera et al. [22]8 3 2 9
Goldar-Najaﬁ et al. [23]9 3 5 2
Hepatitis C + Alcoholic Liver Disease
Burra et al. [25] 84 714 65 261 52 57
Aguilera et al. [24] 8 65 1 7 34 3
Burra et al. [21]8 2 1 6
Dhar et al. [20]7 2 7
Pera et al. [22]8 8 2 1
Goldar-Najaﬁ et al. [23]9 7 3 1
alcoholic liver disease alone [20, 24, 25], in keeping with
otherevidencethat hepatitis C and alcoholact synergistically
to cause more aggressive liver disease. Goldar-Najaﬁ et al.
[23] suggested a diﬀerence in pre-OLT duration of liver
disease between those grafted for ALD alone compared with
thosegrafted for HCV+ ALD(median 25and15 years, resp.,
but the strength of the conclusionsis limited by the numbers
of cases in each groups).
Similarly, Aguilera et al. [24] found that patients with
alcoholic cirrhosis were sicker at the time of transplantation
than those of the HCV and HCV + ALD groups (percentage
of patients with Child-Pugh-Turcotte C: 47%, 30%, and
43%, resp.; mixed versusALD, P = .01). A history of tobacco
consumption was more frequently reported in patients
undergoing transplantation for HCV + ALD and ALD alone
than those with HCV alone (72%, 68%, and 24%, resp.;
HCV versus mixed, P = .001). The incidence of HCC pre-
OLT was greater in HCV and HCV + ALD patients than
in ALD patients (44%, 35%, and 18%, resp.; mixed versus
ALD,P = .01).Similarﬁndings have beenreported by others
authors [22, 23]. Goldar-Najaﬁ et al. [23] reported that the
tumors in the mixed group were larger than those in the
ALD group (mean diameter 4.25 versus 0.85cm). Post-OLT
recurrence ofHCCwas noted in 25% in ALDcompared with
50% in those with HCV + ALD, suggesting the recurrence
rate is related to their size of the tumour at LT rather than
any eﬀect of the coexistent HCV (Table 2).
While there may be some element of selection bias and
diﬀerent patterns of referral for those in the three groups,
those transplanted for ALD and HCV are more likely to
have more aggressive disease pretransplant and have more
advanced disease at the time of transplant.
4.Isthe HCVRecurrenceMore Aggressive in
theHCV-ALDTransplant Patients?
Several studies pointed to a link between alcohol and
progression ofliverdisease duetoviral hepatitis. Alcoholwill
transiently increase circulating levels of HCV RNA, suggest-
ing that alcohol may have a direct eﬀect on viral replication
(26). Patients with HCV infection who have high alcohol
consumptionhavehigherhepaticironconcentrations, which
may aﬀect HCV replication and also perhaps enhance
hepatic ﬁbrogenesis (17). Moreover, the immunologic eﬀects
of alcohol may aﬀect the balance between host and virus,
resulting in more severe liver disease.
However, there is, as yet, no convincing evidence that
HCV recurrence in patients transplanted for HCV + ALD
cirrhosis is more aggressive than that in patients with HCV
cirrhosis alone [23, 24].
No diﬀerences were found in the incidence of severe
recurrent HCV disease (45% in the HCV group versus 45%
in the mixed group, P<. 660), acute hepatitis (26% in the
HCV group versus 28% in the mixed group, P = .854), or
ﬁbrosis stage>1at1year(34%intheHCVgroupversus35%
in the mixed group, P = .88) between patients undergoing
transplantation forHCV-related cirrhosis alone comparedto
those with cirrhosis of mixed etiology [24].
However,theseconclusionsmustbetreatedwithcaution:
numbers are relatively small and many factors (host, viral,4 Journal of Transplantation
Table 2: Baseline pretransplant characteristics by group.
HCV group HCV + alcohol group Alcohol group
Age (years) 50 [20]; 59 [24]; 53 [25] 43 [20]; 48 [22]; 46 [23]; 49 [24]; 49
[25]
51 [20]; 45 [22]; 53 [23]; 53 [24]; 52
[25]
Gender (% men) 51 [20]; 51 [24]; 63 [25] 70 [20]; 79 [22]; 91 [23]; 97 [24]; 88
[25]
81 [20]; 88 [22]; 84 [23]; 87 [24]; 79
[25]
Etnicity
Caucasian (%) 81 [20]7 3 [ 20]9 2 [ 20]
Black (%) 13 [20]2 7 [ 20]4 [ 20]
Others (%) 6 [20]0 [ 20]4 [ 20]
Child-Turcotte-Pugh C (%) 30 [24]5 8 [ 22]; 43 [24]5 2 [ 22]; 47 [24]
Child-Turcotte-Pugh score 8 (5–13) [24] 9 (5–14) [24] 9 (5–13) [24]
HCC (%) 10 [20]; 44 [24]0 [ 20]; 6 [21]; 21 [22]; 35 [24]0 [ 20]; 3 [21]; 3 [22]; 18 [24]
History of tobacco
Consumption (%) 24 [24]7 2 [ 24]6 8 [ 24]
Alcohol intake
0–40g/day (%) 61 [20]0 [ 20]0 [ 20]
40–80g/day (%) 39 [20]0 [ 20]0 [ 20]
>80g/day (%) 0 [20] 100 [20] 100 [20]
Genotype 1 (%) 92 [24]8 1 [ 24]
Pre-OLT duration of the liver
disease in years (median) —1 5 [ 23]2 5 [ 23]
Time on waiting list (days) 56 [24]5 2 [ 24]8 7 [ 24]
graft, and immunosuppression) may aﬀect rates of rate
recurrence.
5.Does AlcoholRecidivismRepresentan
ImportantIssue inTransplanted Patientsfor
HCV-ALDCirrhosis?
The risk of recidivism is a major problem in alcoholic
cirrhotic patients although the actual incidence is diﬃcult
to establish as centers use diﬀerent evaluation methods
[26–29], deﬁnitions of alcohol recurrence, and diﬀerent
followup protocols. The eﬀect of alcohol recidivism in terms
of histological liver damage has been reported in several
studies [30–35], with conﬂicting results in terms of severity
[30, 32, 33, 35, 36]. Determining the contribution of alcohol
and HCV infection to the extent of graft damage can be
diﬃcult [22, 37, 38]. There is no clear deﬁnition of relapse,
and this lack of deﬁnition may explain the widely diﬀerent
relapse rates reported in the literature, ranging from 7% to
95% [35, 39, 40].
Cuadrado et al. showed that heavy drinking reduces the
long-term survival (over 5 years) of patients transplanted for
ALD alone [41]. However, the signiﬁcance of slips remains
uncertain: it has been hypothesized that a slip, which should
always be considered an unwelcome event but, in itself is
unlikelytocauseharm but,formany patientswill progress to
a more damaging pattern of alcohol intake [42]. Thus, most
centers advocate total abstinence in those with a history of
alcohol dependence.
Goldar-Najaﬁ et al. reported a similar rate of relapse to
alcoholic behaviour in ALD and HCV + ALD groups (8,9%
versus 9,4%, resp.), but overall return to heavy drinking
seemed to be uncommon [23]. Aguilera et al. found that
the incidence of alcohol relapse was higher in patients
undergoing transplantation for ALD than in the HCV and
HCV + ALD groups (18%, 3%, and 8%, resp.) [24]. Burra
et al. [21] studied the eﬀect of alcohol recidivism in terms
of liver histopathological damage in patients following liver
transplantation for alcoholic cirrhosis, with or without
concomitant HCV infection. They classiﬁed the patients as
heavy drinkers if they drank more than 200g of alcohol a
week and occasional drinkers if they drank less than 200g
of alcohol a week [33]. No statistically signiﬁcant diﬀerence
emerged between HCV positive heavy drinkers, occasional
drinkers, and abstainers in terms of fatty changes in the
hepatocytes, pericellular ﬁbrosis, and perivenular ﬁbrosis.
Portal tract ﬁbrosis (P = .0005), portal tract monocyte
(P = .003) and lymphocyte (P = .001) inﬂammation,
parenchymal lymphocyte inﬂammation (P = .006), and
perivenular ﬁbrosis (P = .025) were more common in
anti-HCV positive compared with HCV-negative patients,
suggesting graft damage due to the virus damage rather
than with alcohol consumption. However, because of the
relative low rate and short duration of alcohol use following
liver transplantation, these conclusions must be treated with
caution. No signiﬁcant diﬀerences in liver tests were seen at
any time after liver transplantation among the three groups
of drinkers with or without HCV. It seems that the majority
of patients who resume drinking habit after liver transplantJournal of Transplantation 5
consume moderate amounts of alcohol (fewer than 12% of
patients drink >200g of alcohol/week), and therefore such
liver damage is slow to develop.
On the present, limited information, alcohol recidi-
vism after liver transplantation in patients with HCV +
ALD cirrhosis does not appear adversely to inﬂuence liver
morphology or function. The predictors of recidivism of
alcoholism are uncertain [35, 43]. The role ofrecurrent HCV
in inducing the alcohol behaviour or potentiating the injury
is unclear.
6.Isthe WaitingListMortalityand
PosttransplantMortalityIncreased in
PatientsTransplantedforHCV and
AlcoholicCirrhosisComparedwithAlcohol
orHCV InfectionAlone?
HCV patients may be at increased risk for waiting list
mortality when compared with patients without HCV, and
this eﬀect is greater in subjects with both HCV and ALD
[44].OnestudyfromtheUSshowedthatforthosewithHCV
infection,therewasasigniﬁcantly greaterriskofdeathonthe
waiting list (HR 1.19, 95% CI 1.09–1030, P = .001) whereas
for those with ALD there was no signiﬁcant increased risk
of death. However, of those with HCV infection, those with
ALD had a greater risk of waiting list death than those with
HCV alone (HR 1.14, 95% CI 1.04–1.25, P = .006) and
conversely for those with a primary diagnosis of ALD, those
with HCV had a greater risk of waiting list mortality than
those with ALD alone (HR 1.36, 95% CI 1.21–1.53, P<
.0001). Thus, while it may be diﬃcult to distinguish whether
ALDor HCV is the main cause of end-stage liver disease, it is
clear that those with both HCV and ALD are more likely to
die awaiting transplant.
Unadjusted and adjusted posttransplant mortality is
g r e a t e ri nH C V +s u b j e c t st h a nH C V − recipients (HR 1.26,
95% CI 1.10–1.45; P = .0009) whereas ALD did not
inﬂuence posttransplant mortality (HR 0.95). ALD did
not signiﬁcantly contribute to mortality in either HCV+
or HCV− subjects. In contrast, HCV infection increase
posttransplant mortality in both ALD + HCV recipients
(HR 1.30, 95% CI 1.07–1.59; P<. 01) and ALD alone
recipients (HR 1.25, 95% CI 1.08–1.45; P = .004), with the
interaction between HCV and ALD on posttransplantation
mortality being nonsigniﬁcant (Table 3). Thus, while alcohol
c o n s u m p t i o nd o e sl e a dt og r a f tl o s so rp a t i e n td e a t hi n
some recipients, the eﬀect is too small to show statistical
signiﬁcance so the conclusion is likely to represent a type 2
error rather than support the view that a return to alcohol
consumption has no impact on patient or graft survival.
The apparentlackofimpact ofalcoholmay be dueto low
rate of posttransplantation heavy drinking habit relapse and
to the fact that it takes up to 10 years to have an impact on
graft [45–47].
Both ALD and HCV patients showed a survival ben-
eﬁt from liver transplantation. The survival beneﬁt of
transplanted patient for mixed etiology has not been well
evaluated although it is likely to be signiﬁcant.
Table 3: Inﬂuence of diagnosis on pre- and posttransplant
mortality in patients with hepatitis C+ alcoholic cirrhosis.
Pretransplant Posttransplant
A l c o h o l H R1 . 1 4 H R0 . 9 7
95% CI 1.04–1.25 95% CI 0.83–1.13
P = .006 P = .70
Hepatitis C HR 1.36 HR 1.3
95% CI 1.21–1.35 95% CI 1.07–1.59
P = .0001 P = .01
Data from Lucey et al. [44].
7.IsThere AnyDifferencein Termsof
QualityofLife(QOL) amongPatients
Transplanted forHCV+ ALDCirrhosis
ComparedwithPatientsTransplanted for
HCV CirrhosisAlone?
Qualityoflife (QOL)is an important factorin the evaluation
of OLT. The role of HCV infection on QOL and speciﬁcally
the eﬀect of recurrence of the infection after LT has been
the focus of several studies [48–55]. In comparison with
otherOLTindications, hepatitisCreport muchlowerhealth-
related quality of life (HRQOL) scores after transplantation
despite similar survival rates [49, 51, 53, 56, 57]; moreover,
patient knowledge of the diagnosis of recurrent HCV alone
can negatively impact HRQOL [48, 57–61].
Singh et al. evaluated prior alcohol use and the HRQOL
scores of HCV transplanted patients. They found that
Karnofsky scores at 6 months (mean, 82 versus 97) and
12 months (mean, 84 vsersus 85.7), the Beck depression
scores at 6 months (mean, 13.4 vsrsus 14.9) and 12 months
(mean, 19.5 versus 21.5), and quality of life scores at 6
months (mean, 5.0 versus 4.6) and 12 months (mean, 3.5
versus 2.6) did not diﬀer signiﬁcantly between patients
with HCV recurrence and alcohol use and patients with
HCV recurrence without alcohol use [49]. Multiple studies
conﬁrm these ﬁndings and show no signiﬁcant diﬀerence
in HRQOL with alcoholic liver disease as OLT indication
compared with other OLT indications, including HCV [62–
66]. Recently, Ruppert et al. reported that recipients who
had both ALD + HVC, but not either diagnosis alone, had
consistently worse QOL in all domains evaluated (physical
distress, psychological distress, social/role function, personal
function, and general health perception) at the 1-year time
point, and they signiﬁcantly worsen in both physical func-
tioning and physical symptoms over time. These diﬀerences
remain after controlling for other medical factors (age,
MELD scores, etc.) before LT [67].
8.Conclusions
Current evidence suggests that Hepatitis C/Alcohol-related
cirrhosis represents an excellent indication for liver trans-
plantation, and that graft and patient survival are compara-
ble to those of patients with HCV cirrhosis or ALD cirrhosis6 Journal of Transplantation
alone. HCV recurrence in patients with HCV + ALD
cirrhosis undergoing liver transplantation does not seem
more aggressive than that in patients with HCV cirrhosis
alone. A return to alcohol consumption, in the short term at
least in patients with HCV + ALD cirrhosis does not have an
important impact on graft survival in patients with alcohol
and HCV infection. However, outcomes are relatively short
and, given the known interaction of HCV and alcohol on
exacerbation of liver damage in the native liver, it would
seem prudent to advise those grafted for HCV infection to
have a minimal alcohol consumption, and where there is a
history of alcohol dependence, complete abstinence should
be advised.
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